within Pharmacolibrary.Drugs.ATC.H;

model H03AA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 8.333333333333333e-08,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>ATC code:</td><td>H03AA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Combinations of levothyroxine (T4) and liothyronine (T3) are used as replacement therapy in patients with hypothyroidism, often when monotherapy with levothyroxine is not sufficient. Historically used more frequently, such combinations are not the standard of care today in most countries, but are still prescribed in selected cases of thyroid hormone resistance or patient preference.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a typical adult under oral administration. No population-specific published PK data available for the combination, values adapted from monotherapy studies.</p><h4>References</h4><ol><li><p>Alomari, M, et al., &amp; Gaisford, S (2018). Printing T. <i>International journal of pharmaceutics</i> 549(1-2) 363â€“369. DOI:<a href=\"https://doi.org/10.1016/j.ijpharm.2018.07.062\">10.1016/j.ijpharm.2018.07.062</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30063938/\">https://pubmed.ncbi.nlm.nih.gov/30063938</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end H03AA03;
